First Trust Nasdaq Pharmaceuticals ETF Rating $39.78 -0.25 (-0.62%) As of 03:45 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock First Trust Nasdaq Pharmaceuticals ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FTXH Aggregate RatingModerate Buy 2.67Holdings in FTXH have an aggregate rating of Moderate Buy based on 535 analyst ratings issued in the past year covering 25 companies (83.9% of the portfolio).FTXH Aggregate Price Target$39.840.15% UpsideHigh Prediction$39.84Average Prediction$39.84Low Prediction$39.84Holdings in FTXH have an aggregate price target of $39.84 and a range of $39.84 to $39.84 covering 25 companies (83.9% of the portfolio).FTXH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust Nasdaq Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 FTXH Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.56%LLYEli Lilly and Company$1,182.24-2.2%4.732 of 5 stars2.83$1,292.18 9.3%30Trending NewsAnalyst DowngradeInsider TradeAnalyst Revision7.03%ABBVAbbVie$249.20-0.6%4.9053 of 5 stars2.88$275.50 10.6%26Trending NewsAnalyst ForecastAnalyst Revision6.94%MRKMerck & Co., Inc.$135.78+0.2%4.3446 of 5 stars2.68$135.50 -0.2%22Trending NewsAnalyst ForecastInsider TradeAnalyst Revision6.92%JNJJohnson & Johnson$260.44-0.6%4.8022 of 5 stars2.80$268.22 3.0%25Trending News6.88%BMYBristol Myers Squibb$63.86-1.2%4.219 of 5 stars2.52$66.06 3.4%25Trending NewsAnalyst Revision3.65%VTRSViatris$16.23+1.2%2.5827 of 5 stars2.57$17.50 7.8%7Positive News3.60%BIIBBiogen$209.80-0.4%4.0032 of 5 stars2.58$227.07 8.2%33Analyst Downgrade3.50%AMGNAmgen$415.12-0.7%3.8123 of 5 stars2.35$372.39 -10.3%31Analyst ForecastInsider Trade3.47%CAHCardinal Health$234.92+1.6%4.7173 of 5 stars2.83$265.93 13.2%18Earnings ReportDividend AnnouncementAnalyst Forecast3.31%REGNRegeneron Pharmaceuticals$803.44-0.3%3.7808 of 5 stars2.62$793.74 -1.2%26Insider Trade3.27%VRTXVertex Pharmaceuticals$505.46-2.1%4.4256 of 5 stars2.92$563.50 11.5%243.17%PFEPfizer$26.77-0.1%3.6282 of 5 stars2.19$28.28 5.6%21Trending NewsAnalyst Revision2.94%GILDGilead Sciences$138.30+0.1%4.4449 of 5 stars2.83$158.04 14.3%29Trending NewsAnalyst DowngradeOptions VolumeAnalyst Revision2.64%UTHRUnited Therapeutics$499.81-0.3%4.355 of 5 stars2.85$646.00 29.2%13Insider TradeAnalyst Revision2.60%JAZZJazz Pharmaceuticals$245.03-0.3%4.1011 of 5 stars2.95$272.89 11.4%20Analyst Forecast2.45%INCYIncyte$120.18-0.3%3.5373 of 5 stars2.43$120.65 0.4%23Analyst Forecast2.15%ILMNIllumina$190.75-1.0%3.2259 of 5 stars2.47$188.40 -1.2%17Positive News1.97%ZTSZoetis$73.64-2.9%4.7853 of 5 stars2.32$109.62 48.9%19Analyst Forecast1.71%CRLCharles River Laboratories International$279.70-0.6%1.7093 of 5 stars2.69$255.65 -8.6%16Insider Trade1.63%EXELExelixis$51.19+1.2%3.1006 of 5 stars2.32$49.79 -2.7%19Analyst UpgradeInsider Trade1.53%MEDPMedpace$578.18-0.6%3.5613 of 5 stars2.23$584.18 1.0%13Analyst UpgradeInsider Trade1.30%HALOHalozyme Therapeutics$98.70-2.0%3.8753 of 5 stars2.62$91.20 -7.6%13Insider Trade1.27%NBIXNeurocrine Biosciences$152.66+1.2%4.9877 of 5 stars2.88$200.86 31.6%24Analyst Downgrade1.23%ALKSAlkermes$49.11-0.7%3.1203 of 5 stars2.72$54.56 11.1%18Positive News1.18%BMRNBioMarin Pharmaceutical$67.39-1.7%4.8586 of 5 stars2.70$88.00 30.6%23Analyst Downgrade This page (NASDAQ:FTXH) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
